The study was stopped due to patient enrollment challenges.

Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.

Inclusion Criteria:

• Receipt of allogeneic hematopoietic cell transplant >100 days prior to consent
• Documented cGVHD as defined by the NIH consensus criteria in at least one organ system other than the GI tract (for example, cGVHD of the oral cavity would qualify as a criterion)
• Endoscopic findings consistent with GI GVHD
• Must be able to swallow tablets
• Must be able to read and understand informed consent
• Adequate birth control methods for the duration of the study

Exclusion Criteria:

• >500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study drug
• GI infection
• Multi-organ failure or other condition that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
• HIV seropositivity
• Pregnant or nursing female
• Use of any investigational drug to treat chronic GVHD within 28 days of the first dose of study drug
• Evidence of recurrent or progressing malignant disorder that was the indication for HCT